HP Inc vs Zimmer Biomet Holdings Inc — how do they compare? HP Inc trades at $30.23 (market cap $29.25B), while Zimmer Biomet Holdings Inc trades at $89.91 (market cap $16.95B). The key difference: HP Inc is the larger of the two by market cap, and HP Inc pays the higher dividend (3.7%). Which is the better fit depends on your goals — on Pluang, investors hold HP Inc for 69 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| HPQ | ZBH | |
|---|---|---|
Market Cap | $29.25B | $16.95B |
Volume | 10,025,806 | 2,505,240 |
Sector | Technology | Health |
52-Week High | $35.48 | $103.98 |
52-Week Low | $18.20 | $79.58 |
Typical Hold Time | 69 Days | 89 Days |
Enterprise Value | $35.42B | $24.02B |
Dividend Yield | 3.7% | 1.08% |
Signals from Pluang's Aura AI — not financial advice
HPQ trades at $30.2, down 6.33% on the day, amid concerns over a projected mid-single-digit PC sales decline in 2027. The stock shows strong technical momentum with a bullish moving average signal, though RSI levels are mixed. Fundamentally, HPQ maintains solid profitability with a 4.14% net margin and attractive valuation at a P/E of 12.38 and P/S of 0.51. Recent earnings beats highlight operational strength, but negative shareholder equity and high liabilities pose balance sheet risks.
The outlook is cautious; while HPQ's dividend yield of 3.82% and consistent cash flow provide income appeal, near-term headwinds from PC market softness and competitive pressures may limit upside. Analyst consensus is mixed with a $25.75 price target below current levels, suggesting limited near-term growth potential. Investors should weigh stable cash generation against cyclical industry risks and elevated debt.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →